Abstract
Recent progress in molecular and cellular biology has resulted in the development of numerous effective drugs. However, there are still a number of diseases for which no known effective therapy exists, such as ischemic heart disease, vascular bypass graft failure and heart failure. Despite its limitations, oligodeoxynucleotide (ODN)-based therapy is emerging as a potential strategy for the treatment of patients with cardiovascular disease that is resistant to current therapeutic approaches. Indeed, several nucleic acid drugs and delivery methods for heart disease have been developed and their efficacy has been investigated in animal models. Among them, some agents have undergone clinical trials, such as cmyc antisense ODN, E2F and NFκB decoy ODN. However, none of the large randomized placebo-controlled trials has shown conclusive evidence of clinical benefit. Recent experimental studies suggested that siRNA- and miRNA-based strategies have potential as a potent therapeutic approach for the treatment of restenosis. In addition, simultaneous regulation of multiple intracellular signaling pathways is expected to enhance the therapeutic effects. This review focuses on the potential of recent ODN-based gene therapy for the treatment of heart disease, especially restenosis after revascularization.
Keywords: Angioplasty, nucleic acid drug, restenosis, vein graft, ischemic heart disease, vascular bypass graft failure, heart failure, (ODN)-based therapy, siRNA- and miRNA-based strategies, ODN-based gene therapy
Current Topics in Medicinal Chemistry
Title:Nucleic Acid Drugs for Preventing Restenosis after Coronary Revascularization
Volume: 12 Issue: 15
Author(s): Takashi Miyake, Hironori Nakagami and Ryuichi Morishita
Affiliation:
Keywords: Angioplasty, nucleic acid drug, restenosis, vein graft, ischemic heart disease, vascular bypass graft failure, heart failure, (ODN)-based therapy, siRNA- and miRNA-based strategies, ODN-based gene therapy
Abstract: Recent progress in molecular and cellular biology has resulted in the development of numerous effective drugs. However, there are still a number of diseases for which no known effective therapy exists, such as ischemic heart disease, vascular bypass graft failure and heart failure. Despite its limitations, oligodeoxynucleotide (ODN)-based therapy is emerging as a potential strategy for the treatment of patients with cardiovascular disease that is resistant to current therapeutic approaches. Indeed, several nucleic acid drugs and delivery methods for heart disease have been developed and their efficacy has been investigated in animal models. Among them, some agents have undergone clinical trials, such as cmyc antisense ODN, E2F and NFκB decoy ODN. However, none of the large randomized placebo-controlled trials has shown conclusive evidence of clinical benefit. Recent experimental studies suggested that siRNA- and miRNA-based strategies have potential as a potent therapeutic approach for the treatment of restenosis. In addition, simultaneous regulation of multiple intracellular signaling pathways is expected to enhance the therapeutic effects. This review focuses on the potential of recent ODN-based gene therapy for the treatment of heart disease, especially restenosis after revascularization.
Export Options
About this article
Cite this article as:
Miyake Takashi, Nakagami Hironori and Morishita Ryuichi, Nucleic Acid Drugs for Preventing Restenosis after Coronary Revascularization, Current Topics in Medicinal Chemistry 2012; 12 (15) . https://dx.doi.org/10.2174/156802612803531324
DOI https://dx.doi.org/10.2174/156802612803531324 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Coumarin-1,2,3-triazole Hybrid Molecules: An Emerging Scaffold for Combating Drug Resistance
Current Topics in Medicinal Chemistry Sex Hormones, Metabolic Syndrome and Kidney
Current Topics in Medicinal Chemistry Effects of Thiazolidinediones Beyond Glycaemic Control
Current Pharmaceutical Design Progress in the Development of Aminopeptidase N (APN/CD13) Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Biochemical Markers of Cardiovascular Damage from Tobacco Smoke
Current Pharmaceutical Design Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Statin Treatment Non-adherence and Discontinuation: Clinical Implications and Potential Solutions
Current Pharmaceutical Design Health Care Discovery, Novo Nordisk A/S, DK-2880 Bagsværd, Denmark
Current Pharmaceutical Biotechnology Pharmacogenetics in Psychiatry - A Useful Clinical Tool or Wishful Thinking for the Future?
Current Pharmaceutical Design Use of Mouse Models to Evaluate Roles of Nuclear Receptors and their Ligands in the Pathogenesis and Treatment of Atherosclerosis
Current Drug Targets Understanding the Role of Aldose Reductase in Ocular Inflammation
Current Molecular Medicine The Vicious Circle of Leptin and Obesity
Current Nutrition & Food Science Inhibition of Renin-Angiotensin System and Advanced Glycation End Products Formation: A Promising Therapeutic Approach Targeting on Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Diminished Renal Function and the Incidence of Heart Failure
Current Cardiology Reviews Protein Kinases as Drug Targets in Human and Animal Diseases
Current Enzyme Inhibition Cerebral Aneurysm as an Exacerbating Factor in Stroke Pathology and a Therapeutic Target for Neuroprotection
Current Pharmaceutical Design The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature
Current Cardiology Reviews Multiple Drug Resistance Associated with Function of ABC-Transporters in Diabetes Mellitus: Molecular Mechanism and Clinical Relevance
Infectious Disorders - Drug Targets Prevention and treatment of atherosclerosis with flaxseed -derived compound secoisolariciresinol diglucoside
Current Pharmaceutical Design Myocardial Protection Against Ischemia-Reperfusion Injury: Novel Approaches in Maintaining Homeostatic Stability in Blood
Recent Patents on Cardiovascular Drug Discovery